Literature DB >> 2576351

Analysis of the estrogen receptor gene structure in human breast cancer.

E H Koh1, J Ro, D M Wildrick, G N Hortobagyi, M Blick.   

Abstract

We studied the structure of the human estrogen receptor (ER) gene by Southern blot analysis in 34 tumor samples and normal breast tissues or peripheral blood samples from the same patients. No rearrangement or amplification of the ER gene was seen in either ER-positive or ER-negative breast tumors. One patient showed an apparent constitutional deletion of a non-allelic ("invariant") restriction fragment in DNAs from both normal leukocytes and bilateral breast tumors. Of 20 patients constitutionally heterozygous for an ER gene RFLP, only one showed tumor-specific loss of heterozygosity. This is consistent with the ER gene change we noted overall. At the c-myb locus on chromosome 6q adjacent to the ER gene, allele loss occurred in 1 out of 15 informative cases. In addition, tumor-specific allelic loss at the c-H-ras1 locus on chromosome 11p occurred in 4 of 22 informative cases, and at the D17S28 locus on chromosome 17p in 2 of 7 informative cases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2576351

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers.

Authors:  Z Tang; I Treilleux; M Brown
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

2.  Investigation of the origin of variant, truncated estrogen receptor-like mRNAs identified in some human breast cancer biopsy samples.

Authors:  L C Murphy; H Dotzlaw; J Hamerton; J Schwarz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

3.  Responses in the brain of estrogen receptor alpha-disrupted mice.

Authors:  P J Shughrue; D B Lubahn; A Negro-Vilar; K S Korach; I Merchenthaler
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.